Abstract
Lorvotuzumab mertansine, a unique antibody–drug conjugate targeting CD56, is frequently expressed on multiple myeloma cells. The present phase I trial of the single agent describes the maximum tolerated dose, safety, and initial efficacy to aid future drug development.
Original language | English (US) |
---|---|
Pages (from-to) | 29-34 |
Number of pages | 6 |
Journal | Clinical Lymphoma, Myeloma and Leukemia |
Volume | 19 |
Issue number | 1 |
DOIs | |
State | Published - Jan 2019 |
Keywords
- Antibody-drug conjugate
- Drug-development
- Efficacy
- Immunotherapy
- Monoclonal antibody
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research